$31.47
+0.82 (+2.68%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
—
1Y
-1.96%
YTD
+16.64%
Open$31.55
Previous Close$30.65
Day High$32.36
Day Low$31.33
52W High$34.54
52W Low$14.19
Volume—
Avg Volume4.78M
Market Cap8.82B
P/E Ratio83.92
EPS$0.37
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$25.57
Above
RSI (14)
21.6
Oversold
Analyst Ratings
Strong Buy
16 analysts
Price Target
-1.7% upside
Current
$31.47
$31.47
Target
$30.92
$30.92
$20.23
$30.92 avg
$48.05
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.43B | 1.64B | 1.52B |
| Net Income | -119,832,263 | 316.28M | 306.08M |
| Profit Margin | -8.4% | 19.3% | 20.1% |
| EBITDA | 44.53M | 415.16M | 429.14M |
| Free Cash Flow | — | 185.08M | 215.40M |
| Rev Growth | — | +14.2% | +10.8% |
| Debt/Equity | 0.66 | 0.26 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |